Back to search

Peptide record

TPDB09972

R2PLx-22 Antibacterial Anticancer Antifungal Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09972
R2PLx-22
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP Antifungipept CAFPdb
standard
No
A 22-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
GIMDTVKNAAKNLAGQLLDKLK
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C102H181N29O31S1
RCEHFPSWY
LK
2341.79
10.16
4
2
10
+2
1.03
-0.155
115.45
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
4
Residue Composition
number
3
A
0
R
2
N
2
D
0
C
0
E
1
Q
2
G
0
H
1
I
4
L
4
K
1
M
0
F
0
P
0
S
1
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 2 D: 2 C: 0 E: 0 Q: 1 G: 2 H: 0 I: 1 L: 4 K: 4 M: 1 F: 0 P: 0 S: 0 T: 1 W: 0 Y: 0 V: 1
Chemical Descriptors
22 reviewed residue count
C102H181N29O31S1 sequence-only estimate (linear, free termini)
2341.79 sequence-only estimate (linear, free termini)
10.16 sequence-only estimate (linear, free termini)
+2 sequence-only estimate (linear, free termini)
1.03 sequence-only estimate (linear, free termini)
-0.155 sequence-only estimate (linear, free termini)
Free Activity
L Activity
Linear Activity
Free Activity
Antimicrobial Activity
Synthetic Analogue of Ranatuerin-2PLx Synthetic Activity
Evidence Records 10 records
Evidence 1 Activity

Activity

IC50
IC50 = 843.40 µM
Anticancer
843.40 µM

Target

Lung Cancer
H-157
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 872.70 µM
Anticancer
872.70 µM

Target

Skin Cancer
MDA-MB-435S
Skin

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 3 Activity

Activity

IC50
IC50 = 283.90 µM
Anticancer
283.90 µM

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 4 Activity

Activity

IC50
IC50 = 104.10 µM
Anticancer
104.10 µM

Target

Brain Tumor
U-251-MG
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 5 Activity

Activity

IC50
IC50 = 109.30 µM
Anticancer
109.30 µM

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2018
Evidence 6 Activity

Activity

IC50
Toxicity
588.20 µM
Cytotoxic
IC50 | 588.20 | µM | target cell: Human microvascular endothelial cells HMEC-1

Target

Human microvascular endothelial cells HMEC-1

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 7 Activity

Activity

13% Hemolysis
Toxicity
512 µM
Hemolytic Cytotoxic
13% Hemolysis | 512 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 8 Activity

Activity

<5% Hemolysis
Toxicity
256 µM
Hemolytic Cytotoxic
<5% Hemolysis | 256 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018
Evidence 9 Activity

Activity

% Hemolysis
Toxicity
3 %
Hemolytic
Hemolytic_activity: [Ref.30279210] 3% hemolysis at 1 µM , 4% hemolysis at 2 µM , 1% hemolysis at 4 µM , 0% hemolysis at 8 µM , 2% hemolysis at 16 µM , 0% hemolysis at 32 µM , 0% hemolysis at 128 µM , 3% hemolysis at 256 µM , 13% hemolysis at 512 µM against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2018 Nov 9 38(6). pii: BSR20180710. doi: 10.1042/BSR20180710.
Evidence 10 Activity

Activity

IC50
Toxicity
588.20 µM
Hemolytic Cytotoxic
Hemolytic_activity: Horse erythrocytes: Low haemolytic activity | Cytotoxicity: HMEC-1: IC50=588.20 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Biosci Rep. 2018 Nov 9 38(6):BSR20180710.